1
Home
Companies

Pharma Mar

#4579

Rank

$1.74B

Marketcap

ES Spain

Country

Pharma Mar
Leadership team

Mr. Jose Maria Fernandez Sousa-Faro (Founder, Exec. Chairman, CEO & Pres)

Mr. Pedro Francisco Fernandez Puentes (Exec. Vice-Chairman)

Mr. Juan Carlos-Torres Carretero (Founder)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Colmenar Viejo, Madrid, Spain
Established
1986
Net Income
100M - 500M
Revenue
100M - 500M
Traded as
PHM.MC
Social Media
URL
https://www.pharmamar.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
History

The company was founded in 1986, starting as an R&D unit of Spanish pharmaceutical company Zeltia. Its focus was on developing methods to treat diseases caused by genetic defects, such as cancer and autoimmune disorders. The first drug developed by the company, KYNic (Kytril®) was approved by the European Medicines Agency in 1995. Since then, Pharma Mar has grown to become a leader in oncology, with over 20 approved products now available in over 70 countries, and more than 150 clinical studies in progress.

Mission
The mission of Pharma Mar is to continue to be a leader in the development of innovative cancer and autoimmune treatments, through scientific and comprehensive research, and to fill the unmet medical needs of patients.
Vision
Pharma Mar's vision is to provide world-class treatments and services to cancer and autoimmune patients worldwide, while maintaining the highest standards of quality, safety and efficiency.
Key Team

Ms. María Luisa de Francia Caballero (Chief Financial Officer)

Ms. Elena Calleja Crespo (Director of Fin. & Admin.)

Mr. José Luis Moreno Martinez-Losa (Director of Capital Markets & Investor Relations)

Mr. Juan Gomez Pulido (Gen. Counsel & Sec. of the Board of Directors)

Ms. Sandra Llamera Sanchez (Global Compliance Head)

Ms. Lara Vadillo (Communication Director)

Mr. Juan Nogues (Director of International Marketing & Sales)

Recognition and Awards
Pharma Mar has been awarded numerous awards, including the European Organisation for Research and Treatment of Cancer/American Society of Clinical Oncology’s Merit Award for its contribution to cancer research, the Roche Award for its contribution to knowledge of oncology, and the Innovation in Oncology Award for its innovation in cancer drug development.
References

https://en.wikipedia.org/wiki/PharmaMar

https://in.investing.com/equities/pharma-mar-sau

https://finance.yahoo.com/quote/PHM.MC/profile?p=PHM.MC

https://www.crunchbase.com/organization/pharmamar-zeltia-group

https://companiesmarketcap.com/

https://www.pharmamar.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Pharma Mar
Leadership team

Mr. Jose Maria Fernandez Sousa-Faro (Founder, Exec. Chairman, CEO & Pres)

Mr. Pedro Francisco Fernandez Puentes (Exec. Vice-Chairman)

Mr. Juan Carlos-Torres Carretero (Founder)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Colmenar Viejo, Madrid, Spain
Established
1986
Net Income
100M - 500M
Revenue
100M - 500M
Traded as
PHM.MC
Social Media
URL
https://www.pharmamar.com